Looking forward to the upcoming new technologies and tools in 2017 is the New Year's practice. In fact, before 2017 has arrived, we have already predicted that 2017 will be an important year. After all, Medtronic released the first hybrid closed-loop system in the spring of 2016, which opened up a new era of artificial pancreas technology. And this is just one of the exciting developments we've been looking forward to this year.
Artificial pancreas system
Medtronic's Minimed 670G: In September 2016, the FDA reviewed the Minimed 670G, the world's first system to regulate insulin delivery based on CGM (continuous blood glucose monitoring) values, which allows users to be as close as possible to their blood glucose goals. The value is 120 mg/dL. The device itself will be equipped with a vertical design layout and a color display. However, the device does not support data sharing. The Minimed 670G features the new Guardian 3CGM sensor, which has improved its accuracy and credibility. The system is directly linked to the Bayer Contour Link 2.4 hand pointer. In 2016, Ascensia blood glucose meter introduced Bayer Contour Link 2.4 hand pointer stab instrument, allowing the instrument to remotely control the use of insulin pills. When talking about the release date of 670G, Medtronic only said "early 2017."
Tandem's first generation of automated insulin delivery devices (AIDs): Manufacturers of insulin pumps plan to release the first generation of closed-loop systems by the end of 2017. The device's characteristic is to predict hypoglycemia pauses (PLGS), which in many ways reflect what the MedT system needs first. The Tandem Diabetes Care Process line shows the current situation and the company's development plans for the next few years.
Other artificial pancreatic systems: Yes, we are also observing many other closed-loop systems projects—Bigfoot, iLET, etc.—but we don't expect these to be achieved in 2017, and we need to continue research and experimentation (R&D) .
Medtronic
In addition to closed-loop projects (or can be called cross-projects, depending on who you are asking), Medtronic tells us that they are working on a "holistic" approach to CGM, mobile app and data analysis. In one. Spokesperson Pam Reese said that this is probably the project worth looking forward to in 2017.
Independent CGM: “The development of an independently operated CGM system will be our first step. The independent CGM system can provide insulin injections to users based on real-time data from sensors on the user's smartphone. The system also has text information. The warning feature allows the guardian to receive alerts for high blood sugar levels or low blood sugar levels via the phone. In addition, the system will have the option to automatically upload daily sensor information to CareLink Pro software, allowing health care providers to obtain useful data. Providing care to people with diabetes and adjusting treatments as needed. This will provide clinicians with more point data on trends in blood sugar levels, helping doctors see new conditions and help patients with diabetes optimize treatment method."
Fufeng Sinuote Biotechnology Co.,Ltd. , https://www.ffsinuoteplant.com